Palvella Therapeutics, Inc. Increase (Decrease) in Accounts Payable, Trade
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Accounts Payable, Trade of $2.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-04
- Palvella Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was $1.35M, a 1064.66% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $851.00K, a 24.29% decline year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was $1.16M, a 2588.37% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was -$1.14M, a 167.42% decline year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2025 was $1.26M, a 43.70% decline from fiscal 2024.
- Palvella Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2024 was $2.24M.
- Palvella Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2023 was -$2.25M.
- Palvella Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2022 was -$4.21M, a 159.70% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month | Increase (Decrease) in Accounts Payable, Trade 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.20M 10-Q · filed 2026-08-04 | $3.36M derived: sum of 3 quarters · filed 2026-08-04 | $2.22M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $851.00K 10-Q · filed 2026-05-07 | $2.01M derived: sum of 2 quarters · filed 2026-05-07 | $871.00K derived: sum of 3 quarters · filed 2026-05-07 | $987.00K derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $20.00K derived: sum of 2 quarters · filed 2026-03-31 | $136.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.26M 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.02M derived: sum of 2 quarters · filed 2026-08-04 | $104.00K 10-Q · filed 2025-11-12 | $147.00K derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.24M 10-Q · filed 2026-08-04 | $1.28M derived: sum of 3 quarters · filed 2026-08-04 | $2.97M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $1.12M 10-Q · filed 2026-05-07 | $1.17M derived: sum of 2 quarters · filed 2026-05-07 | $2.85M derived: sum of 3 quarters · filed 2026-05-07 | $3.28M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.73M derived: sum of 2 quarters · filed 2026-03-31 | $2.15M derived: sum of 3 quarters · filed 2026-03-31 | $2.24M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.11M derived: sum of 2 quarters · filed 2025-11-12 | $2.19M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $425.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $510.00K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $85.00K 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -$2.25M 10-K · filed 2025-03-31 | -$789.00K 10-K · filed 2024-03-29 | |||
| 2022-12-31 | -$4.21M 10-K · filed 2024-03-29 | ||||
| 2021-12-31 | $7.05M 10-K · filed 2023-03-31 | ||||
| 2020-12-31 | -$4.35M 10-K · filed 2022-03-02 | ||||
| 2019-12-31 | $1.26M 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | $764.00K 10-K · filed 2020-03-13 | ||||
| 2017-12-31 | -$186.77K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$2.32M derived: sum of 2 quarters · filed 2019-03-18 | -$595.02K derived: sum of 3 quarters · filed 2019-03-18 | -$332.00K 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$408.26K derived: sum of 2 quarters · filed 2017-11-13 | -$145.23K 10-Q · filed 2017-11-13 | -$2.09M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2017-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $1.99M 10-Q · filed 2017-08-11 | $42.84K derived: sum of 3 quarters · filed 2018-03-15 | $3.00M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2017-03-31 | $263.02K 10-Q · filed 2017-05-15 | -$1.68M derived: sum of 2 quarters · filed 2018-03-15 | $1.27M derived: sum of 3 quarters · filed 2018-03-15 | $1.03M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $1.01M derived: sum of 2 quarters · filed 2018-03-15 | $762.81K derived: sum of 3 quarters · filed 2018-03-15 | $1.36M 10-K · filed 2018-03-15 | $1.36M 10-K · filed 2017-03-30 |
| 2016-09-30 | $2.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $2.71M derived: sum of 2 quarters · filed 2017-11-13 | $3.30M 10-Q · filed 2017-11-13 | $3.26M derived: sum of 4 quarters · filed 2017-11-13 | |
| 2016-06-30 | -$246.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $350.54K 10-Q · filed 2017-08-11 | $309.05K derived: sum of 3 quarters · filed 2017-08-11 | -$637.51K derived: sum of 4 quarters · filed 2017-08-11 | |
| 2016-03-31 | $597.19K 10-Q · filed 2017-05-15 | $555.69K derived: sum of 2 quarters · filed 2017-05-15 | -$390.87K derived: sum of 3 quarters · filed 2017-05-15 | $65.62K derived: sum of 4 quarters · filed 2017-05-15 | |
| 2015-12-31 | -$41.50K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$988.05K derived: sum of 2 quarters · filed 2017-03-30 | -$531.57K derived: sum of 3 quarters · filed 2017-03-30 | -$90.92K 10-K · filed 2017-03-30 | |
| 2015-09-30 | -$946.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$490.08K derived: sum of 2 quarters · filed 2016-11-10 | -$49.43K 10-Q · filed 2016-11-10 | $1.07M derived: sum of 4 quarters · filed 2016-11-10 | |
| 2015-06-30 | $456.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $897.13K 10-Q · filed 2016-08-11 | $2.02M derived: sum of 3 quarters · filed 2016-08-11 | $1.53M derived: sum of 4 quarters · filed 2016-08-11 | |
| 2015-03-31 | $440.65K 10-Q · filed 2016-05-12 | $1.56M derived: sum of 2 quarters · filed 2016-05-12 | $1.07M derived: sum of 3 quarters · filed 2016-05-12 | $1.19M derived: sum of 4 quarters · filed 2016-05-12 | |
| 2014-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $628.39K derived: sum of 2 quarters · filed 2016-03-23 | $745.87K derived: sum of 3 quarters · filed 2016-03-23 | $1.12M 10-K · filed 2016-03-23 | |
| 2014-09-30 | -$490.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$373.45K derived: sum of 2 quarters · filed 2015-11-13 | -$3.32K 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | $117.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $487.60K 10-Q · filed 2015-08-13 | |||
| 2014-03-31 | $370.12K 10-Q · filed 2015-05-14 | ||||
| 2013-12-31 | -$549.40K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |